GlassScriptPhysician profile
Shashank S Sheth
NPI 1528272432
$33,080.95
in general payments reported to CMS, 2019-2025
38 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $227 · 2021: $844 · 2022: $1,887 · 2023: $2,043 · 2024: $7,102 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,450 · Consulting Fee: $8,724 · Food and Beverage: $6,940 · Travel and Lodging: $3,445 · Honoraria: $175 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,450.00 |
| Consulting Fee | $8,724.00 |
| Food and Beverage | $6,940.42 |
| Travel and Lodging | $3,445.31 |
| Honoraria | $175.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21,306.76 | 2019-2025 | Xolair |
| Genzyme Corporation | $3,340.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,729.78 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,599.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $711.67 | 2019-2025 | Dupixent |
| Optinose US, INC. | $516.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $442.63 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Csl Behring | $391.16 | 2019-2025 | Hizentra, Andembry |
| Amgen INC. | $390.84 | 2021-2025 | Tezspire |
| Kaleo, INC. | $321.78 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $298.69 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $266.68 | 2025 | Neffy |
| Alk-Abello, INC | $249.84 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Aimmune Therapeutics, INC. | $218.37 | 2021-2023 | |
| Grifols USA, LLC | $177.37 | 2024-2025 | Xembify |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashank Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.